HUMA

Humacyte, Inc. is a clinical-stage biotechnology company developing a universal, off-the-shelf human acellular vessel (HAV) for vascular repair and reconstruction. The company's investigational HAV technology is a bioengineered tissue designed to replace or repair damaged blood vessels and other tubular structures in the body. Humacyte's lead product candidate is being studied in multiple clinical trials for applications including vascular trauma, arteriovenous access for hemodialysis, and peripheral arterial disease. The HAV is produced from human vascular cells and extracellular matrix, then processed to remove cells, creating a vessel that can be stored and used when needed without requiring immunosuppression. Founded in 2004 and headquartered in Durham, North Carolina, Humacyte went public via SPAC merger in 2021.